Skip to main content

Ocugen, Inc.

corporate_fare Company Profile

Ocugen, Inc.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed OCGN - Latest Insights

OCGN
Apr 28, 2026, 7:01 AM EDT
Filing Type: DEFA14A
Importance Score:
7
OCGN
Apr 20, 2026, 5:18 PM EDT
Filing Type: PRER14A
Importance Score:
8
OCGN
Apr 17, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
OCGN
Mar 27, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
OCGN
Mar 26, 2026, 7:13 PM EDT
Filing Type: 8-K
Importance Score:
8
OCGN
Mar 24, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
OCGN
Mar 23, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
OCGN
Mar 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
OCGN
Mar 04, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
9
OCGN
Mar 04, 2026, 11:38 AM EST
Filing Type: 10-K
Importance Score:
9
OCGN
Mar 04, 2026, 11:12 AM EST
Filing Type: 8-K
Importance Score:
8
OCGN
Mar 04, 2026, 11:07 AM EST
Filing Type: 8-K
Importance Score:
7
OCGN
Mar 04, 2026, 8:15 AM EST
Source: Reuters
Importance Score:
7
OCGN
Mar 04, 2026, 8:15 AM EST
Source: GlobeNewswire
Importance Score:
8
OCGN
Mar 02, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
7
OCGN
Feb 09, 2026, 7:59 AM EST
Filing Type: 8-K
Importance Score:
7
OCGN
Jan 23, 2026, 8:12 AM EST
Filing Type: 8-K
Importance Score:
7
OCGN
Jan 21, 2026, 5:29 PM EST
Filing Type: 8-K
Importance Score:
7
OCGN
Jan 21, 2026, 5:27 PM EST
Filing Type: 424B5
Importance Score:
8
OCGN
Jan 15, 2026, 8:31 AM EST
Filing Type: 8-K
Importance Score:
9